Literature DB >> 25512374

Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells.

Eugénie Goupil1, Dany Fillion1, Stéphanie Clément1, Xiaoyan Luo2, Dominic Devost1, Rory Sleno1, Darlaine Pétrin1, H Uri Saragovi3, Éric Thorin2, Stéphane A Laporte4, Terence E Hébert5.   

Abstract

The angiotensin II type I (AT1R) and the prostaglandin F2α (PGF2α) F prostanoid (FP) receptors are both potent regulators of blood pressure. Physiological interplay between AT1R and FP has been described. Abdominal aortic ring contraction experiments revealed that PGF2α-dependent activation of FP potentiated angiotensin II-induced contraction, whereas FP antagonists had the opposite effect. Similarly, PGF2α-mediated vasoconstriction was symmetrically regulated by co-treatment with AT1R agonist and antagonist. The underlying canonical Gαq signaling via production of inositol phosphates mediated by each receptor was also regulated by antagonists for the other receptor. However, binding to their respective agonists, regulation of receptor-mediated MAPK activation and vascular smooth muscle cell growth were differentially or asymmetrically regulated depending on how each of the two receptors were occupied by either agonist or antagonist. Physical interactions between these receptors have never been reported, and here we show that AT1R and FP form heterodimeric complexes in both HEK 293 and vascular smooth muscle cells. These findings imply that formation of the AT1R/FP dimer creates a novel allosteric signaling unit that shows symmetrical and asymmetrical signaling behavior, depending on the outcome measured. AT1R/FP dimers may thus be important in the regulation of blood pressure.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Allosteric Regulation; Angiotensin II; Dimerization; G Protein; G Protein-coupled Receptor (GPCR); Prostaglandin

Mesh:

Substances:

Year:  2014        PMID: 25512374      PMCID: PMC4317038          DOI: 10.1074/jbc.M114.631119

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Identifying off-target effects and hidden phenotypes of drugs in human cells.

Authors:  Marnie L MacDonald; Jane Lamerdin; Stephen Owens; Brigitte H Keon; Graham K Bilter; Zhidi Shang; Zhengping Huang; Helen Yu; Jennifer Dias; Tomoe Minami; Stephen W Michnick; John K Westwick
Journal:  Nat Chem Biol       Date:  2006-05-07       Impact factor: 15.040

2.  A guided tour into subcellular colocalization analysis in light microscopy.

Authors:  S Bolte; F P Cordelières
Journal:  J Microsc       Date:  2006-12       Impact factor: 1.758

3.  Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases.

Authors:  B C Berk
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

4.  CrossTalk opposing view: Weighing the evidence for class A GPCR dimers, the jury is still out.

Authors:  Nevin A Lambert; Jonathan A Javitch
Journal:  J Physiol       Date:  2014-06-15       Impact factor: 5.182

5.  The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition.

Authors:  K Siddiquee; J Hampton; D McAnally; Lt May; Lh Smith
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

6.  Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK.

Authors:  Eugénie Goupil; Veronica Wisehart; Etienne Khoury; Brandon Zimmerman; Sahar Jaffal; Terence E Hébert; Stéphane A Laporte
Journal:  Mol Endocrinol       Date:  2012-05-25

7.  Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer.

Authors:  Matthew R Whorton; Beata Jastrzebska; Paul S-H Park; Dimitrios Fotiadis; Andreas Engel; Krzysztof Palczewski; Roger K Sunahara
Journal:  J Biol Chem       Date:  2007-11-22       Impact factor: 5.157

8.  Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex.

Authors:  Leo T O Lee; Stephanie Y L Ng; Jessica Y S Chu; Revathi Sekar; Kaleeckal G Harikumar; Laurence J Miller; Billy K C Chow
Journal:  FASEB J       Date:  2014-03-05       Impact factor: 5.191

9.  Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling.

Authors:  Jean-Pierre Vilardaga; Viacheslav O Nikolaev; Kristina Lorenz; Sébastien Ferrandon; Zhenjie Zhuang; Martin J Lohse
Journal:  Nat Chem Biol       Date:  2008-01-13       Impact factor: 15.040

10.  Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer.

Authors:  Juan José Fung; Xavier Deupi; Leonardo Pardo; Xiao Jie Yao; Gisselle A Velez-Ruiz; Brian T Devree; Roger K Sunahara; Brian K Kobilka
Journal:  EMBO J       Date:  2009-09-17       Impact factor: 11.598

View more
  21 in total

1.  Conformational Profiling of the AT1 Angiotensin II Receptor Reflects Biased Agonism, G Protein Coupling, and Cellular Context.

Authors:  Dominic Devost; Rory Sleno; Darlaine Pétrin; Alice Zhang; Yuji Shinjo; Rakan Okde; Junken Aoki; Asuka Inoue; Terence E Hébert
Journal:  J Biol Chem       Date:  2017-02-17       Impact factor: 5.157

Review 2.  AT1 receptor signaling pathways in the cardiovascular system.

Authors:  Tatsuo Kawai; Steven J Forrester; Shannon O'Brien; Ariele Baggett; Victor Rizzo; Satoru Eguchi
Journal:  Pharmacol Res       Date:  2017-05-17       Impact factor: 7.658

Review 3.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 4.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

5.  Conformational biosensors reveal allosteric interactions between heterodimeric AT1 angiotensin and prostaglandin F2α receptors.

Authors:  Rory Sleno; Dominic Devost; Darlaine Pétrin; Alice Zhang; Kyla Bourque; Yuji Shinjo; Junken Aoki; Asuka Inoue; Terence E Hébert
Journal:  J Biol Chem       Date:  2017-06-05       Impact factor: 5.157

Review 6.  Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Pharmacol Res       Date:  2017-06-23       Impact factor: 7.658

7.  Regulation of the thrombin/protease-activated receptor 1 axis by chemokine (CXC motif) receptor 4.

Authors:  Xianlong Gao; You-Hong Cheng; Garrett A Enten; Anthony J DeSantis; Vadim Gaponenko; Matthias Majetschak
Journal:  J Biol Chem       Date:  2020-08-24       Impact factor: 5.157

8.  Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.

Authors:  Anne-Julie Chabot-Doré; Magali Millecamps; Lina Naso; Dominic Devost; Phan Trieu; Marjo Piltonen; Luda Diatchenko; Carolyn A Fairbanks; George L Wilcox; Terence E Hébert; Laura S Stone
Journal:  Neuropharmacology       Date:  2015-08-06       Impact factor: 5.250

9.  β-Arrestin-mediated Angiotensin II Signaling Controls the Activation of ARF6 Protein and Endocytosis in Migration of Vascular Smooth Muscle Cells.

Authors:  Ricardo Charles; Yoon Namkung; Mathieu Cotton; Stéphane A Laporte; Audrey Claing
Journal:  J Biol Chem       Date:  2015-12-24       Impact factor: 5.157

10.  BRET-based effector membrane translocation assay monitors GPCR-promoted and endocytosis-mediated Gq activation at early endosomes.

Authors:  Shane C Wright; Viktoriya Lukasheva; Christian Le Gouill; Hiroyuki Kobayashi; Billy Breton; Samuel Mailhot-Larouche; Élodie Blondel-Tepaz; Nichelle Antunes Vieira; Claudio Costa-Neto; Madeleine Héroux; Nevin A Lambert; Lucas Tabajara Parreiras-E-Silva; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.